Clinical Trials on HER2 Amplified Breast Cancer
Total 11632 results
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedAdvanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)United States, Belgium, Canada, Italy, Spain, United Kingdom
-
Puma Biotechnology, Inc.CompletedHER2 Amplified Breast CancerPortugal
-
Merrimack PharmaceuticalsCompletedMetastatic Breast Cancer | Her2 Amplified Solid TumorsUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein OverexpressionUnited States
-
Orum Therapeutics USA, Inc.RecruitingHER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionUnited States
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Jazz PharmaceuticalsBeiGene, Ltd.Active, not recruitingHER2-amplified Biliary Tract CancersUnited States, Spain, United Kingdom, Korea, Republic of, Canada, China, Italy, Chile, France
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
Ambrx, Inc.WithdrawnHER2 Mutation-Related Tumors | HER2 Amplified Solid TumorsUnited States
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)RecruitingHER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of BreastUnited States
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
-
AstraZenecaDaiichi SankyoNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerCanada
-
QuantumLeap Healthcare CollaborativeByondis B.V.WithdrawnOvarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditionsUnited States
-
Daiichi SankyoCompletedHER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast CancerUnited States
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
National Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseActive, not recruitingBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast CancerUnited States
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Not yet recruitingMetastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast CancervUnited States
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
Washington University School of MedicineMolecular Templates, Inc.WithdrawnHER2-positive Solid Tumor | HER-2 Positive Cancer
-
Enliven TherapeuticsRecruitingColorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid TumorsUnited States
-
Seagen Inc.CompletedHER2 Positive Metastatic Breast CancersUnited States
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer | Inflammatory Breast Cancer Stage III | HER2 Low Breast AdenocarcinomaUnited States
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
-
Seagen Inc.CompletedHER2 Positive Breast CancersUnited States, Canada
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseActive, not recruitingBreast Cancer, Male | HER2-positive Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Residual Disease | HER2 Positive Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast CarcinomaUnited States
-
MedSIRMacroGenics; Seagen Inc.WithdrawnAdvanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
-
Hebei Medical University Fourth HospitalRecruitingAdvanced Breast Cancer | HER2-positive Breast CancerChina
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
-
Saint Luke's Health SystemNovartis PharmaceuticalsRecruitingMetastatic Breast Cancer | HER2-negative Breast CancerUnited States
-
Royal Marsden NHS Foundation TrustPfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave... and other collaboratorsRecruitingHER2-negative Breast Cancer | ER+ Breast CancerUnited Kingdom, France
-
Shandong Cancer Hospital and InstituteUnknownMetastatic Breast Cancer | HER2-positive Breast Cancer
-
Rawalpindi Medical CollegeCompleted
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
National Cancer Institute (NCI)TerminatedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditionsUnited States
-
Hoffmann-La RocheCompletedHER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast CancerIndia